Back to Ask the Diabetes Team Ask the Diabetes Team

From Portland, Oregon, USA:

I was just reading about the Iacocca Foundation and their fight for a cure for type 1 diabetes. The theory is that they have a drug that will kill the bad white blood cells that attack the pancreas and, once they are killed, the pancreas will begin on its own to regenerate new islet cells. I guess it's worked in mice. In your opinion, how promising does this sound and is this kind of a cure, if it were to come about, only for those who have just developed the disease? Would it benefit at all those who have been living with diabetes for years?


There are many such projects, all in their infancy. Some are funded by the ADA, some by JDRF, some by NIH, some by private foundations like Iacocca. I suspect you are talking about the project at Massachusetts General Hospital. But, nobody knows if these project will work in people, what the side effects will be, exactly who and when candidates might be chosen, etc. It's terrific that private foundations such as Iacocca's will fund such projects when they do not get funding elsewhere. Time will tell whether or not they turn out to be interesting theories that do not work or can be developed to be safe and workable.


Original posting 17 Aug 2005
Posted to Research: Cure


  Back to Ask the Diabetes Team Return to the Top of This Page

Last Updated: Tuesday April 06, 2010 15:10:04
This Internet site provides information of a general nature and is designed for educational purposes only. If you have any concerns about your own health or the health of your child, you should always consult with a physician or other health care professional.

This site is published by T-1 Today, Inc. (d/b/a Children with Diabetes), a 501c3 not-for-profit organization, which is responsible for its contents. Our mission is to provide education and support to families living with type 1 diabetes.
By using this site, you agree to our Terms of Use, Legal Notice, and Privacy Policy.
© Children with Diabetes, Inc. 1995-2018. Comments and Feedback.